Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ACC 2016 BEST OF THE REST: Surgery Trials, More CoreValve Data, Leadless Pacemakers, Drug-Filled Stents, And More

This article was originally published in Clinica

Executive Summary

Almost 19,000 people were in Chicago April 2-4 for the 2016 American College of Cardiology's Annual Scientific Sessions, which featured over 2,400 presentations, including 24 late-breaking trials and 10 other clinical research presentations. Edwards’ transcatheter valves grabbed most of the headlines, but here are some of the other highlights from medical device trial results presented at the meeting

You may also be interested in...

TCT 2018: Medtronic's CoreValve Proves Durable Out To Five Years

The five-year results from the US pivotal high-risk trial of Medtronic's CoreValve transcatheter aortic valve, the longest-term follow-up data from a randomized trial of CoreValve, show the valve remains durable with low rates of severe hemodynamic structural valve deterioration compared to surgical valves.

ACC 2017: SURTAVI Supports Intermediate-Risk Intervention For Medtronic's CoreValve

In an interview with Medtech Insight, the lead investigator of SURTAVI, an ongoing trial of Medtronic's CoreValve in intermediate risk patents, says transcatheter aortic valve is continuously improving and will probably soon be indicated for even low-risk patients, but that surgical valve replacement will have an important role to play for the foreseeable future.

US FDA Approves First Intermediate-Risk Indication For TAVR

The expanded indication for Edwards' Sapien XT and Sapien 3 arrives about when the company had predicted.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts